Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.
Type:
Grant
Filed:
July 13, 2007
Date of Patent:
February 1, 2011
Assignee:
LG Life Sciences Ltd.
Inventors:
Sung Pil Choi, In Ae Ahn, Sang Hyup Lee, Sang Dae Lee, Mi Sook Shin, Koo Lee, Deog Young Choi, Dong Sup Shim, Hyeon Joo Yim, Min Kyung Yoon, Soo Yong Chung, Jung Ae Lee, Yong Hwa Ha, Young Kwan Kim, Oeuk Park, Hyun Min Lee, Youn Hoa Kim
Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.
Type:
Application
Filed:
September 29, 2010
Publication date:
January 27, 2011
Applicant:
LG Life Sciences, Ltd., Inc.
Inventors:
Myung-Jin KIM, Sun-Jin Kim, Oh-Ryong Kwon
Abstract: Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Type:
Application
Filed:
December 19, 2008
Publication date:
October 28, 2010
Applicant:
LG LIFE SCIENCES, LTD.
Inventors:
Chang-Seok Lee, Hyeon Joo Yim, Kyoung-Hee Kim, Jaeick Lee, Sung-Hack Lee, Kyu Woong Lee, Hee Bong Lee, Wan Su Park, Changhee Min
Abstract: The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient.
Type:
Application
Filed:
December 22, 2008
Publication date:
October 21, 2010
Applicant:
LG Life Sciences Ltd.
Inventors:
Soon Ha Kim, Sung Bae Lee, Seung Hyun Yoon, Mi Kyoung Cho, Kyoung Hee Kim, Heui Sul Park, Hyoung Jin Kim
Abstract: Disclosed is a process for preparing a compound of the following formula (2): including the steps of reacting a compound of the following formula (4): with trityl chloride to prepare trityloxy-acetic acid ethyl ester of the following formula (8): reacting the compound of formula (8) with ethyl magnesium halide to prepare 1-trityloxymethyl-cyclopropanol of the following formula (9): combining the 1-trityloxymethyl-cyclopropanol of formula (9) with diisopropylbromo-methylphosphonate in a solvent in the presence of a base to prepare (1-trityloxymethyl-cyclopropoxymethyl)-phosphonic acid diisopropyl ester of the following formula (10): as a solid form, and converting the trityl group of the compound of formula (10) into a hydroxyl group.
Abstract: The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.
Type:
Application
Filed:
August 18, 2008
Publication date:
August 19, 2010
Applicant:
LG Life Sciences Ltd.
Inventors:
Soon Ha Kim, Hyoung Jin Kim, Sun Young Koo, Sung Bae Lee, Heui Sul Park, Seung Hyun Yoon, Seung Yup Paek, Hyo Shin Kwak, Dong Ook Seo, Eok Park
Abstract: The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient.
Type:
Application
Filed:
August 18, 2008
Publication date:
August 5, 2010
Applicant:
LG Life Sciences Ltd
Inventors:
Soon Ha Kim, Hyoung Jin Kim, Sun Young Koo, Chul Woong Chung, Sung Bae Lee, Heui Sul Park, Seung Hyun Yoon, Hyo Shin Kwak, Dong Ook Seo, Eok Park
Abstract: The present invention relates to a composition for detection of HCV by a single step reaction, comprising a specific primer and probe. In particular, the present invention relates to a composition for detection of HCV by a single step reaction, comprising the primer sequences of SEQ ID NOs:1 and 2; a composition for detection of HCV by a single step reaction, comprising both the primer sequences and a probe of SEQ ID NOs:5 or 9; a method for detecting HCV by a single step reaction, comprising the steps of obtaining a sample from a subject, and amplifying and detecting HCV using the primer and probe; and a kit comprising the primer and probe, in which the HCV detection method is characterized by a single step reaction.
Type:
Application
Filed:
December 29, 2009
Publication date:
July 8, 2010
Applicant:
LG LIFE SCIENCES LTD.
Inventors:
Dong Hwan LEE, Jin Seok Kang, Jae Sung Lee, Young Suk Park, Dong Hyun Kim
Abstract: The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.
Type:
Grant
Filed:
September 9, 2009
Date of Patent:
May 25, 2010
Assignee:
LG Life Sciences Ltd.
Inventors:
Dong-Gyu Cho, Jae-Hong Lim, Jae-Taeg Hwang, Woo-Young Cho, Hyun-Sook Jang, Chang-Ho Lee, Tae-Saeng Choi, Chung-Mi Kim, Yong-Zu Kim, Tae-Kyun Kim, Seung-Joo Cho, Gyoung-Won Kim, Jong-Ryoo Choi, Jeong-Min Kim, Kee-Yoon Roh
Abstract: The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.
Type:
Application
Filed:
November 10, 2009
Publication date:
May 13, 2010
Applicant:
LG LIFE SCIENCE LTD.
Inventors:
Koo Lee, Sang Dae Lee, Sang Pil Moon, In Ae Ahn, Sung Pil Choi, Hyun Ho Lee, Dong Sup Shim, Soo Yong Chung, Hyun Min Lee
Abstract: The present invention relates to a pharmaceutical composition for treating alcohol-induced liver injury comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof, and a use thereof.
Type:
Application
Filed:
November 13, 2008
Publication date:
May 13, 2010
Applicant:
LG Life Sciences Ltd.
Inventors:
Hye Kyung CHANG, Yeong Soo OH, Hyun Ik SHIN, Mi Jeong PARK, Jung Gyu PARK, Yong Han PAIK
Abstract: A composition comprising 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate hydrate and their use in antibacterial therapy.
Type:
Grant
Filed:
December 7, 2006
Date of Patent:
April 20, 2010
Assignee:
LG Life Sciences, Ltd.
Inventors:
Ae Ri Kim, Jin Hwa Lee, Ki Sook Park, Jong Ryoo Choi, Tae Hee Lee, Jay Hyok Chang, Do Hyun Nam, Hoon Choi
Abstract: Provided is a PNA (Peptide Nucleic Acid) chip in which a probe PNA containing a desired DNA sequence is immobilized on a plastic substrate coated with an epoxy group-containing polymer. Therefore, single-stranded PNAs can be immobilized on a transparent plastic substrate by means of an epoxy group-containing polymer layer in an efficient and cost-effective manner. Fluorescence signal detection based on PNA/DNA hybridization enables identification of SNP (Single Nucleotide Polymorphism).
Type:
Grant
Filed:
June 21, 2005
Date of Patent:
April 13, 2010
Assignee:
LG Life Sciences, Ltd.
Inventors:
Jeongmin Ha, Jae Young Jang, In Soo Kim
Abstract: The present invention relates to a process for the preparation of 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate, a key intermediate of quinolone antibiotics. According to the process of the present invention, the total number of steps has been shortened to 2-3 steps, the solid separation is not required, and the use of costly chemicals, particularly (BOC)2O (t-butoxycarbonyl anhydride), several organic solvents and reactants, is eliminated.
Abstract: The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.
Type:
Application
Filed:
October 26, 2007
Publication date:
February 18, 2010
Applicant:
LG Life Sciences Ltd.
Inventors:
Hye Kyung Chang, Yeong Soo Oh, Yong Jin Jang, Sung Sub Kim, Kyeong Sik Min, Chul Woong Chung, Mi Jeong Park, Jung Gyu Park
Abstract: The present invention relates to a novel process for the production of 3-amino-5-fluoro-4-dialkoxypentanoic acid ester used in the precursor of 3-amino-5-fluoro-4-oxopentanoic acid, represented by the following formula (1): wherein R1 and R2 are as defined in the Description.
Type:
Application
Filed:
August 9, 2007
Publication date:
February 11, 2010
Applicant:
LG Life Sciences Ltd.
Inventors:
Hyun Ik Shin, Hyeong Wook Choi, Jae Hoon Lee, Kyu Woong Lee
Abstract: The present invention relates to a pyridone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.
Type:
Application
Filed:
October 26, 2007
Publication date:
January 21, 2010
Applicant:
LG Life Sciences Ltd.
Inventors:
Hye Kyung Chang, Yeong Soo Oh, Yong Jin Jang, Sung Sub Kim, Kyeong Sik Min, Chul Woong Chung, Mi Jeong Park, Jung Gyu Park
Abstract: The present invention relates to a process for preparing a beta-keto ester compound of formula (1), which is an intermediate for the synthesis of quinolone antibiotics. Particularly, the present invention is characterized by the reaction of an organo nitrile compound with a salt of mono-alkyl malonate in the presence of metal salt, and so the reaction is easy to control due to its endothermic nature, and is devoid of lachrymatory reagents with excellent reproducibility. Subsequent in situ hydrolysis in the presence of aqueous acid solution provided the compound of formula (1).
Type:
Grant
Filed:
September 15, 2006
Date of Patent:
January 5, 2010
Assignee:
LG Life Sciences Ltd.
Inventors:
Hyun Ik Shin, Bo Seung Choi, Jae Hoon Lee
Abstract: The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3?5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same.
Abstract: The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.
Type:
Application
Filed:
July 27, 2007
Publication date:
November 26, 2009
Applicant:
LG LIFE SCIENCES LTD.
Inventors:
Hye Kyung Chang, Yeong-Soo Oh, Yong-Jin Jang